Biosyent Inc. (RX) - Total Liabilities
Based on the latest financial reports, Biosyent Inc. (RX) has total liabilities worth CA$7.88 Million CAD (≈ $5.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Biosyent Inc. to track the company's year-over-year net asset growth rate.
Biosyent Inc. - Total Liabilities Trend (1997–2024)
This chart illustrates how Biosyent Inc.'s total liabilities have evolved over time, based on quarterly financial data. See RX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Biosyent Inc. Competitors by Total Liabilities
The table below lists competitors of Biosyent Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InflaRx N.V
F:IF0
|
Germany | €13.66 Million |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
Indonesia | Rp1.83 Trillion |
|
QES Group Bhd
KLSE:0196
|
Malaysia | RM124.77 Million |
|
1911 Gold Corp
V:AUMB
|
Canada | CA$9.87 Million |
|
Amber International Holding Limited
NASDAQ:AMBR
|
USA | $133.01 Million |
|
Paxman AB
ST:PAX
|
Sweden | Skr59.89 Million |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
Korea | ₩148.78 Billion |
|
Servotronics Inc
NYSE MKT:SVT
|
USA | $13.01 Million |
Liability Composition Analysis (1997–2024)
This chart breaks down Biosyent Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosyent Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosyent Inc. (1997–2024)
The table below shows the annual total liabilities of Biosyent Inc. from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$6.36 Million ≈ $4.60 Million |
-6.10% |
| 2023-12-31 | CA$6.77 Million ≈ $4.90 Million |
-4.96% |
| 2022-12-31 | CA$7.12 Million ≈ $5.15 Million |
+26.91% |
| 2021-12-31 | CA$5.61 Million ≈ $4.06 Million |
-17.16% |
| 2020-12-31 | CA$6.78 Million ≈ $4.90 Million |
+31.03% |
| 2019-12-31 | CA$5.17 Million ≈ $3.74 Million |
+44.32% |
| 2018-12-31 | CA$3.58 Million ≈ $2.59 Million |
+23.89% |
| 2017-12-31 | CA$2.89 Million ≈ $2.09 Million |
+14.69% |
| 2016-12-31 | CA$2.52 Million ≈ $1.82 Million |
+2.64% |
| 2015-12-31 | CA$2.46 Million ≈ $1.78 Million |
-1.14% |
| 2014-12-31 | CA$2.48 Million ≈ $1.80 Million |
+100.89% |
| 2013-12-31 | CA$1.24 Million ≈ $894.76K |
+52.07% |
| 2012-12-31 | CA$813.36K ≈ $588.37K |
+92.57% |
| 2011-12-31 | CA$422.37K ≈ $305.54K |
+64.88% |
| 2010-12-31 | CA$256.17K ≈ $185.31K |
+82.07% |
| 2009-12-31 | CA$140.70K ≈ $101.78K |
-50.17% |
| 2008-12-31 | CA$282.37K ≈ $204.26K |
+50.57% |
| 2007-12-31 | CA$187.53K ≈ $135.66K |
-18.18% |
| 2006-12-31 | CA$229.20K ≈ $165.80K |
+7.47% |
| 2005-12-31 | CA$213.28K ≈ $154.28K |
-31.80% |
| 2004-12-31 | CA$312.72K ≈ $226.21K |
+87.79% |
| 2003-12-31 | CA$166.53K ≈ $120.46K |
+59.78% |
| 2002-12-31 | CA$104.22K ≈ $75.39K |
-91.78% |
| 2001-12-31 | CA$1.27 Million ≈ $917.17K |
+31.50% |
| 2000-12-31 | CA$964.15K ≈ $697.45K |
+20.52% |
| 1999-12-31 | CA$800.00K ≈ $578.71K |
+60.00% |
| 1998-12-31 | CA$500.00K ≈ $361.69K |
-16.67% |
| 1997-12-31 | CA$600.00K ≈ $434.03K |
-- |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more